Top 5 drug products advertised in professional health journals (dollars) through May 2013

Xarelto remains the top drug product being advertised in professional health journals year-to-date by both pages and dollars, according to Kantar Media. Invokana is a new-comer to the list this month. It was approved by the FDA at the end of March and is used for the treatment of adults with type 2 diabetes.

Top 5 Print Ad Drugs (Dollars): Jan. – May 2013

  1. Xarelto Tablets - $8 MM (+30%)
  2. Linzess Capsules - $5 MM (N/A)
  3. Tudorza Pressair Inhalation Powder - $4 MM (N/A)
  4. Invokana - $3 MM (N/A)
  5. Zytiga - $2 MM (+50%)

Xarelto ranked #3 at this time in 2012, while Linzess, Tudorza Pressair Inhalation Powder and Invokana did not appear on the list.

The percentage changes compare January – May 2013 to that same time period in 2012.For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.



Search article